World's Best Scientists 2026 revealed!
Martin J. van den Bent

Martin J. van den Bent

D-Index & Metrics

Medicine

D-Index
129
Citations
103861
World Ranking
2521
National Ranking
98

Overview

Martin J. van den Bent is affiliated with Erasmus University Rotterdam in the Netherlands. Their research primarily focuses on medical fields, with a significant concentration on genetics, pulmonary and respiratory medicine, radiology, nuclear medicine and imaging, neurology, and molecular biology.

Their main topics of study cover glioma diagnosis and treatment, brain metastases and treatment, radiomics and machine learning in medical imaging, meningioma and schwannoma management, neuroblastoma research and treatments, medical imaging techniques and applications, and the use of MRI in cancer diagnosis.

The frequent publication venues for Martin J. van den Bent include Neuro-Oncology, Neuro-Oncology Advances, Journal of Clinical Oncology, The Lancet Oncology, and European Journal of Cancer.

Their body of work includes recent papers such as:

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020, Nature Reviews Clinical Oncology)
  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions (2020, Neuro-Oncology)
  • Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline (2021, Journal of Clinical Oncology)
  • Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma (2023, New England Journal of Medicine)
  • EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours (2021, Annals of Oncology)

Collaborations are a notable part of their research practice, frequently working with coauthors such as Michael Weller, Patrick Y. Wen, Wolfgang Wick, Pim J. French, and Marion Smits.

Best Publications

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

    Roger Stupp;Warren P. Mason;Martin J. van den Bent;Michael Weller

  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

    Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent

  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy

  • Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

    Dieta Brandsma;Lukas Stalpers;Walter Taal;Peter Sminia

  • Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

    Martin J. van den Bent;Alba A. Brandes;Martin J.B. Taphoorn;Johan M. Kros

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

    Michael Weller;Martin van den Bent;Matthias Preusser;Emilie Le Rhun

  • Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma

    Francesco Pignatti;Martin van den Bent;Desmond Curran;Channa Debruyne

  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

    Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge

  • Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

    Martin J. van den Bent;Antoine F. Carpentier;Alba A. Brandes;Marc Sanson

  • European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

    Michael Weller;Martin van den Bent;Jörg C Tonn;Roger Stupp

  • Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

    Walter Taal;Hendrika M Oosterkamp;Annemiek M E Walenkamp;Hendrikus J Dubbink

  • Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

    Lauren E. Abrey;Tracy T. Batchelor;Andrés J.M. Ferreri;Mary Gospodarowicz

  • Response assessment criteria for brain metastases: proposal from the RANO group

    Nancy U Lin;Eudocia Q Lee;Hidefumi Aoyama;Igor J Barani

  • Lomustine and Bevacizumab in Progressive Glioblastoma

    Wolfgang Wick;Thierry Gorlia;Martin Bendszus;Martin Taphoorn

  • MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

    Michael Weller;Roger Stupp;Guido Reifenberger;Alba A. Brandes

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Patrick Y. Wen;Michael Weller;Eudocia Quant Lee;Brian M. Alexander

  • EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

    Michael Weller;Martin van den Bent;Kirsten Hopkins;Jörg C Tonn

  • Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

    Lonneke A M Gravendeel;Mathilde C M Kouwenhoven;Olivier Gevaert;Johan J de Rooi

  • Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

    Martin J. van den Bent;Alba A. Brandes;Roy Rampling;Mathilde C.M. Kouwenhoven

  • Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial

    René Olivier Mirimanoff;Thierry Gorlia;Warren Mason;Martin J. Van Den Bent

Frequent Co-Authors

Michael Weller
Michael Weller University of Zurich
Johan M. Kros
Johan M. Kros Erasmus University Rotterdam
Wolfgang Wick
Wolfgang Wick German Cancer Research Center
Roger Stupp
Roger Stupp Northwestern University
Alba A. Brandes
Alba A. Brandes Institute of Neurological Sciences
Patrick Y. Wen
Patrick Y. Wen Harvard University
Michael A. Vogelbaum
Michael A. Vogelbaum Cleveland Clinic
Monika E. Hegi
Monika E. Hegi University of Lausanne
Pieter Wesseling
Pieter Wesseling University of Amsterdam
Marion Smits
Marion Smits Erasmus University Rotterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA doesn’t always mean becoming a physician. There are many related online degrees and flexible career pathways in healthcare. For those interested in managing healthcare systems, a health administration degree can open doors to supervisory and leadership roles in hospitals and clinics.

Registered nurses seeking career advancement should consider adn to fnp programs, which enable nurses with an associate’s degree to move directly into family nurse practitioner positions through convenient online bridge programs.

Nutrition is another pathway with growing demand. Earning an online bachelor's in nutrition is ideal for those passionate about health promotion, dietary planning, and patient counseling.

For working professionals aiming for higher administrative roles, selecting whats the best online mha program for working adults can help balance career growth with a busy schedule, leading to executive opportunities in healthcare organizations.

These online options deliver flexibility, allowing you to advance your education and navigate diverse healthcare career paths on your own terms.

Best Scientists Citing Martin J. van den Bent

Trending Scientists

Recently Published Articles